AbbVie Presents Phase II Data for HUMIRA in HS Patients
October 03, 2013 at 06:16 AM EDT
AbbVie (NYSE: ABBV ) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1 Efficacy results were reported using a novel Hidradenitis Suppurativa Clinical Response (HiSCR) endpoint
